946 related articles for article (PubMed ID: 18986295)
1. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
Bartlett JG
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
[TBL] [Abstract][Full Text] [Related]
2. Importance of atypical pathogens of community-acquired pneumonia.
Plouffe JF
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S35-9. PubMed ID: 10984326
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein for discriminating treatment failure from slow responding pneumonia.
Ruiz-González A; Falguera M; Porcel JM; Martínez-Alonso M; Cabezas P; Geijo P; Boixeda R; Dueñas C; Armengou A; Capdevila JA; Serrano R
Eur J Intern Med; 2010 Dec; 21(6):548-52. PubMed ID: 21111942
[TBL] [Abstract][Full Text] [Related]
4. Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia.
Lui G; Ip M; Lee N; Rainer TH; Man SY; Cockram CS; Antonio GE; Ng MH; Chan MH; Chau SS; Mak P; Chan PK; Ahuja AT; Sung JJ; Hui DS
Respirology; 2009 Nov; 14(8):1098-105. PubMed ID: 19818051
[TBL] [Abstract][Full Text] [Related]
5. [Determination of serologic markers against bacterial atypical pneumonia agents in pneumonia patients].
Pinar A; Ercis S; Ulukavak T; Dursun B; Hasçelik G
Mikrobiyol Bul; 2004; 38(1-2):27-32. PubMed ID: 15293899
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM
Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993
[TBL] [Abstract][Full Text] [Related]
8. The atypical pneumonias: clinical diagnosis and importance.
Cunha BA
Clin Microbiol Infect; 2006 May; 12 Suppl 3():12-24. PubMed ID: 16669925
[TBL] [Abstract][Full Text] [Related]
9. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
Nakamura S; Yanagihara K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Senjyu H; Saito A; Kohno S
J Infect; 2009 Sep; 59(3):222-4. PubMed ID: 19592113
[No Abstract] [Full Text] [Related]
10. Chlamydia pneumoniae and Mycoplasma pneumoniae.
Blasi F; Tarsia P; Aliberti S; Cosentini R; Allegra L
Semin Respir Crit Care Med; 2005 Dec; 26(6):617-24. PubMed ID: 16388430
[TBL] [Abstract][Full Text] [Related]
11. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia.
Falguera M; Ruiz-González A; Schoenenberger JA; Touzón C; Gázquez I; Galindo C; Porcel JM
Thorax; 2010 Feb; 65(2):101-6. PubMed ID: 19703825
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of Chlamylege, a new commercial test allowing simultaneous detection and identification of Legionella, Chlamydophila pneumoniae, and Mycoplasma pneumoniae in clinical respiratory specimens by multiplex PCR.
Ginevra C; Barranger C; Ros A; Mory O; Stephan JL; Freymuth F; Joannès M; Pozzetto B; Grattard F
J Clin Microbiol; 2005 Jul; 43(7):3247-54. PubMed ID: 16000443
[TBL] [Abstract][Full Text] [Related]
13. Community-acquired pneumonia: role of atypical organisms.
Cosentini R; Tarsia P; Blasi F; Roma E; Allegra L
Monaldi Arch Chest Dis; 2001 Dec; 56(6):527-34. PubMed ID: 11980285
[TBL] [Abstract][Full Text] [Related]
14. [Atypical pneumonia].
Szilasi M
Orv Hetil; 2005 Aug; 146(34):1759-66. PubMed ID: 16184877
[TBL] [Abstract][Full Text] [Related]
15. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
[TBL] [Abstract][Full Text] [Related]
16. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
Roig J; Casal J; Gispert P; Gea E
Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177
[TBL] [Abstract][Full Text] [Related]
17. [Atypical infection of the respiratory tract and bronchial asthma].
Jahnz-Rózyk K; Targowski T
Pol Merkur Lekarski; 2007 Nov; 23(137):325-7. PubMed ID: 18361312
[TBL] [Abstract][Full Text] [Related]
18. [Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia].
Sáez-Llorens X; Castaño E; Wubbel L; Castrejón MM; de Morales I; Vallarino D; de Atencio I; Muñiz L; Olsen K; McCracken GH
Rev Med Panama; 1998 Sep; 23(2):27-33. PubMed ID: 11214557
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of different nucleic acid amplification techniques for the detection of M. pneumoniae, C. pneumoniae and Legionella spp. in respiratory specimens from patients with community-acquired pneumonia.
Loens K; Beck T; Ursi D; Overdijk M; Sillekens P; Goossens H; Ieven M
J Microbiol Methods; 2008 Jun; 73(3):257-62. PubMed ID: 18378345
[TBL] [Abstract][Full Text] [Related]
20. The role of atypical pathogens in community-acquired pneumonia.
Gupta SK; Sarosi GA
Med Clin North Am; 2001 Nov; 85(6):1349-65, vii. PubMed ID: 11680106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
